Methodological rigor integrated with operational excellence forms a core value of WCT and one of its principal differentiators.  This philosophy is reflected in all aspects of program as well as protocol development, and extends from "first in man" trials and proof of concept paradigms through peri-approval investigations designed to highlight clinical attributes of a new product prior to commercialization or establish a basis for reimbursement decisions.

Contingent upon phase of development and hypotheses to be addressed, the scope of data reviewed includes all aspects of preclinical pharmacology, toxicology, and biodisposition/ pharmacokinetics that might potentially inform the design of an investigation. These data in turn could impact patient and subject characteristics designed to enhance signal detection, the dose range to be evaluated and methods of dosage escalation or termination, structural elements of a protocol including adaptive designs and more traditional interim analyses, the selection of both pharmacodynamic as well as clinical based outcome measures, and all "rules of engagement" regarding data acquisition and approach to biostatistical analyses. 

Facilities within the WCT organization also permit the development of novel assays for either efficacy or safety assessments; full pharmacokinetic analysis capabilities including PK/PD modeling, and innovative as well as traditional biostatistical approaches to all outcomes assessed. Never developed in isolation, all WCT sanctioned protocols are fully vetted through the operational components of the organization and no protocol or proposed program is recommended without full knowledge of logistical and financial implications in addition to the clinical and regulatory ones.